Pharma Industry News

NICE rejects rare blood cancer treatment Poteligeo in final appraisal

Final appraisal document said that clinical trial evidence for Poteligeo is ‘very uncertain’Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]